Scientific and clinical expertise are the pillars of our work
Esmethadone (REL-1017) is an investigational compound. Safety and efficacy have not been established, and no regulatory authority has approved this product for any indication. Statements herein reflect interpretations of published or presented data.
Our team has been collaborating for years with leading experts in the field of neuropsychiatry, such as Maurizio Fava, Steven Stahl and Thomas Kosten. Esmethadone's peer reviewed articles are authored by leading scientists in the field
Our scientists and clinicians have worked in top medical institutions, including, among others, Harvard University, Cornell University, the University of Texas, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, Massachusetts General Hospital.
Leadership
Paolo Manfredi, MD
Chief Scientific Officer and Chief Executive Officer
Paolo Manfredi is a neurologist and co-founder of Medeor Inc. a joint venture with Cornell Center for Technology Enterprise & Commercialization (CCTEC). Medeor then merged to form Relmada Therapeutics, a publicly traded biotechnology company. Dr. Manfredi is a co-inventor of several pharmaceutical patents currently under development. REL-1017 (esmethadone), a well tolerated and safe oral, once-daily NMDA receptor antagonist is currently in Phase 3 for the adjunctive treatment of major depressive disorder. REL-P11 (MR psilocybin), under development by NeuroArbor Therapeutics Inc., has successfully completed a Phase 1 study in overweight-obese subjects and in normal BMI subjects and is preparing for Phase 2 studies.
Marco Pappagallo, MD
Chief Medical Officer and Head of Safety
Marco Pappagallo is a Neurologist and Clinical Professor of Anesthesiology at Albert Einstein College of Medicine, New York. Marco is an internationally renowned researcher and lecturer with over 100 publications and a seasoned inventor of pharmaceuticals. Marco has conducted (PI) clinical trials sponsored by NIH, Glaxo, Roche, and Pfizer and has held CMO positions in several biotechnology companies, including Relmada Therapeutics. Marco is a co-inventor on the psilocybin platform, which includes REL-P11, a Phase 2-ready molecule.
Marco Massini
Chief Financial Officer
Marco Massini is an investor, board director, and operating CFO with deep experience in financial strategy, M&A, and value creation for private-equity-backed companies. He has supported the growth and financial governance of 15+ portfolio companies across consumer, industrial, and technology sectors. His expertise spans enterprise valuation, budgeting and forecasting, cash-flow optimization, debt and equity structuring, turn-around support and board-level reporting, with a strong focus on cross-border operations between the U.S. and Europe. Marco holds an MBA from Columbia Business School and a B.S. in Mechanical Engineering from the University of Parma.
Board of Directors
Andrea Alimonti
Andrea Alimonti is Head of Molecular Oncology, Director of the Institute of Oncology Research, and Professor of Oncology at the Università della Svizzera Italiana. He previously worked at Cornell University and Harvard University, and is the recipient of ERC and J. Steiner Cancer Research awards. Author of publications in leading journals including Nature and Cell, Dr. Alimonti specializes in advancing novel cancer therapies from research to clinical application.
Giorgio Andreacci
Giorgio Andreacci is an entrepreneur and executive with international experience in technology, innovation, and corporate strategy. He co-founded Infinity Technology Solutions S.p.A. and later founded Demetra Technologies Srl, where he serves as President and Board Director. He also holds several institutional roles, including Chairman of the Executive Board of Dixet Group, Supervisory Board Member of SIIT, and Board Member of Genova Smart City Association.
Paolo Manfredi, MD
Paolo Manfredi is a neurologist and co-founder of Medeor Inc., created in partnership with the Cornell Center for Technology Enterprise & Commercialization. Medeor later merged into Relmada Therapeutics, where Dr. Manfredi contributed to the development of several pharmaceutical patents. Among them are REL-1017 (esmethadone), currently in Phase 3 for major depressive disorder, and REL-P11 (MR psilocybin), now preparing for Phase 2 studies.